NEW DELHI: The $100-million domestic insulin therapy market is expected to attain a size of $1 billion over 10 years, with biotech companies such as Biocon trying to grab a slice of the segment. Globally, the $6.5 billion insulin market is expected to be a $10-billion opportunity by 2010.While Pfizer recently announced that it would stop manufacturing the world’s first inhalable insulin mainly due to commercial reasons, others like Eli Lilly, Novo Nordisk and even domestic company, Biocon are racing to develop products to deliver insulin to diabetics in a pain-free and comfortable manner.
